A comprehensive review on bioactive peptides derived from milk and milk products of minor dairy species

Snigdha Guha†, Heena Sharma††, Gaurav Kr Deshwal‡ and Priyanka Singh Rao*‡

Abstract

Milk from different species has been exploited for the isolation of various functional ingredients for decades. Irrespective of the source, milk is considered as a complete food, as it provides essential nutrients required by the human body. Proteins and their fractions are valuable sources of bioactive peptides that might exert a health beneficial role in the human body such as immune-modulation, antioxidant activity, ACE-inhibitory activity, anti-neoplastic, anti-microbial, etc. In milk, bioactive peptides may either be present in their natural form or released from their parental proteins due to enzymatic action. The increasing interest in bioactive peptides among researchers has lately augmented the exploration of minor dairy species such as sheep, goat, camel, mithun, mare, and donkey. Alternative to cow, milk from minor dairy species have also been proven to be healthier from infancy to older age owing to their higher digestibility and other nutritive components. Therefore, realizing the significance of milk from such species and incentivized interest towards the derivatization of bioactive peptides, the present review highlights the significant research achievements on bioactive peptides from milk and milk products of minor dairy species.

Keywords: Milk protein, Bioactive peptides, Camel, Goat, Sheep, Donkey

Introduction

Milk occupies an essential component of the human diet globally. Reports suggest that dairy products are being consumed by more than 6 billion people across the world (FAO 2013). Various species have been utilized for the production of milk. The majority of milk comes from dairy cows and buffaloes followed by other minor dairy species including goats, sheep, camels, yak, mare, donkey, Mithun, etc. Each species has its significance according to its predominance in a particular region or country. However, cows contribute 85% of the world’s total milk production while other minor dairy species such as buffalo, goat, sheep, and camel contribute 11, 2.3, 1.4, and 0.2%, respectively (Gerosa and Skoet 2012). Milk, a lacteal secretion from healthy milch animal, contains numerous nutrients including proteins, carbohydrates, fats, minerals, and vitamins, and thus possess a wide range of nutritional and functional properties. Although the milk composition of any species is based on the requirement of the neonate (Gobbetti et al. 2007; McGrath et al. 2016; Park 2009a), it has also been explored for additional health benefits for infants, children, and adults of mammalian species, beyond their basic nutritive role (Park 2009b). Among various nutrients, protein (3.2 g/100 mL) is one of the most functionally diverse nutrients, and its level and functional properties differ among different species (Regester et al. 1997). Functionally, milk proteins provide a characteristic structure, solubility, water binding, viscosity, and heat stabilization properties to dairy products (Augustin and...
Udabage 2007; Korhonen and Pihlanto-Leppala 2004). From the nutritional point of view, the milk protein is enriched with bioactive substances. Milk protein and their fractions are valuable sources of bioactive peptides with various biological activities such as, antithrombotic, antimicrobial, antioxidative, antihypertensive, immunomodulatory, and sometimes they possess multifunctional activity (Park and Nam 2015). The importance of milk from minor dairy species is growing worldwide. Reports indicate that the world production of non-bovine milk was increased by 165% from 1983 to 2013 while bovine milk production had shown an increase by only 41% (Nuñez and de Renobales 2016). Milk from these minor species not only plays a vital role for producers but also for consumers worldwide. Intense research has been carried out on bioactive peptides, their identification, characterization, and utilization in functional foods, from cow’s milk and milk products. However, since the last two decades, few studies have been focused on the exploration of proteins and their fractions from minor dairy species, particularly for the presence of bioactive peptides. The majority of the work is focused on the release of peptides during in vivo or in vitro digestion of proteins (Giacometti and Buretić-Tomljanović 2017). Hence, there still exists untapped and unexplored knowledge in milk and milk products from minor dairy species mainly in the area of bioactive peptides. To the best of our knowledge, very little and scattered information is available in the literature regarding the bioactive peptides from minor dairy species. Therefore, this review focuses on the gross composition of milk, bioactive peptides derived from milk and milk products of minor dairy species, and their physiological roles in the human body.

Gross composition of milk from minor dairy species

The main intent of milk production, for all terrestrial mammals, is to suffice the nutritional requirements of the neonates. Therefore, milk of all species broadly constitutes the same nutrients, such as proteins, carbohydrates, fat, minerals and water. In addition to these macronutrients, milk also constitutes several biologically active compounds such as growth factors, immunoglobulins, antimicrobial proteins, antibacterial peptides, and hormones, to help the neonates with various physiological functions (Alichanidis et al. 2016). However, among various species, the milk composition, both major and minor constituents, differs depending on nutritional, genetic, and environmental factors. The milk composition also determines its appropriateness as a raw material for various dairy products, its nutritive value, as well as its organoleptic and physicochemical characteristics (Alichanidis et al. 2016). Furthermore, it has also been observed that ruminant and non-ruminant milk is generally distinctive based on their composition. For instance, ruminant milk is characterized by a high total solid content with a higher fat, protein, and ash content (Medhammar et al. 2012; Potočnik et al. 2011). On the other hand, non-ruminant milk such as those of mare, donkey, and humans, constitute more lactose content (Guo et al. 2007; Martini et al. 2014) Nowadays, milk is regarded as one of the most exclusively complete foods which have become a fundamental part of the human diet. Table 1 provides the gross composition of milk across various minor dairy species covered under this review.

Gross composition of protein fraction in milk of minor dairy species

Milk proteins can be broadly divided into three major fractions, namely, casein, whey protein, and non-protein nitrogenous fraction. Milk casein is characterized as the protein that precipitates at isoelectric pH 4.6, whereas whey protein fraction comprises of all the other non-casein proteins which remain soluble. Milk also consists of small amounts of nitrogenous compounds, which are not part of any protein, and are known as non-protein nitrogen (NPN). This includes free amino acids, peptides, creatine, urea, ammonia, uric acid, orotic acid (Michaelidou 2008). Casein is heterogeneous and it contains four major forms: αs1-casein, αs2-casein, β-casein, and κ-casein (Eigel et al. 1984). Ruminant milk consists of casein as the major protein fraction, whereas, in non-ruminant milk, whey protein content is characteristically higher than casein fraction. The casein to whey protein ratio largely varies among different species of mammals. For instance, in mare milk, the ratio is 50:50, human milk is 40:60, whereas, in sheep, goats, cows, and buffaloes, the ratio is around 80:20. Moreover, the different forms of caseins are found in different proportions in milk from different species. For example, β-casein is the dominant form in both goat and camel milk (Al Haj and Al Kanhal 2010; Kappeler et al. 2003; Moatsou et al. 2006), whereas β-casein and αs-casein are the main forms in mare milk (Malacarne et al. 2002).

Whey proteins can be further classified as α-lactalbumin, β-lactoglobulin, immunoglobulins, blood serum albumin

| Species | Total solids | Protein | Lactose | Fat | Ash |
|---------|-------------|---------|---------|-----|-----|
| Camel   | 14.4        | 3.7     | 5.1     | 4.9 | 0.7 |
| Goat    | 12.1        | 3.1     | 4.6     | 3.5 | 0.8 |
| Sheep   | 16.3        | 5.5     | 4.6     | 5.3 | 0.9 |
| Yak     | 16.8        | 5.2     | 4.6     | 7.0 | –   |
| Donkey  | 10.2        | 1.7     | 4.6     | 6.9 | 1.2 |
| Mare    | 11.0        | 2.7     | 6.1     | 1.6 | 0.5 |

The table is adapted and modified from (Park and Haenlein 2006)
(BSA), and miscellaneous minor proteins. α-lactalbumin is the most common constituent of whey protein which is found in the milk of all mammals and plays a major role in the synthesis of the milk sugar, lactose. β-lactoglobulin is the major whey protein found in the milk, however, it is not present in camel and human milk. β-lactoglobulin accounts for about 50% of the total whey proteins in ruminant milk and about 35% in donkey and mare milk (Alichanidis et al. 2016). The NPN content in the milk of mammals is highly variable and it is influenced by breed, herd, lactation, seasons, and feeding practices. For instance, the NPN content in mare milk is around 10–15% of the total milk nitrogen content, in cow milk, it is 5%, whereas in human milk it is about 25%. Ruminant milk has about 3–5% NPN, and, sheep and goat have higher content than cow milk. The most dominant fraction in the NPN is urea, which can account for about 50% of the total nitrogen content of NPN. The next most abundant component is the free amino acids, which accounts for about 16% in sheep milk, 10–20% in cow milk, and about 9–10.5% in goat milk. Taurine, citrulline, and ornithine, which are not a part of protein-bound amino acids, are also found in certain milk. Taurine is a growth modulator and membrane stabilizer found in the milk of all mammals and plays a major role in the synthesis of the milk sugar, lactose.

β-casein (22%) and κ-casein (20%) in cow milk, and about 9–10.5% in goat milk. Taurine, citrulline, and ornithine, which are not a part of protein-bound amino acids, are also found in certain milk. Taurine is a growth modulator and membrane stabilizer and plays a significant role in the formation of bile acids. Taurine is the most abundant amino acid in goat milk followed by human milk. Table 2 gives a detailed comparative view of the protein composition profile of milk from different mammals.

**Bioactive peptides derived from milk of minor dairy species**

**Camel milk**

Camel milk has a special significance in human nutrition, particularly in hot and arid countries. The global production of camel milk is estimated to be 5.3 million tons, with Somalia being the major producer (Food and Agriculture Organization of the United Nations n.d.). Camel milk consists of four major types of caseins, namely, αs1-casein, αs2-casein, β-casein, and κ-casein. Among these, β-casein content was the highest (65%), followed by αs1-casein (22%) and κ-casein (3%) (Farrell et al. 2004). Furthermore, camel milk has been reported to be more susceptible to digestion with chymotrypsin, suggesting the fact that a large number of potential bioactive peptides could be generated from camel milk (Salami et al. 2008). The presence of such bioactive peptides from camel milk has been listed as follows:

**Antioxidant peptides**

Hydrolysis of camel milk using pepsin-pancreatin enzymes yielded peptides with antioxidant and anti-cytotoxic activity (Homayouni-Tabrizi et al. 2017). Concentration and purification of the peptides were achieved through ultrafiltration and reverse phase liquid chromatography, respectively. Three peptides with sequences LEQQQTDEEQDQQL (MW: 1860.85 Da, LL-15), YLEELHLNLAP (MW: 1477.63 Da, YY-11), and RGLHPVPQ (MW: 903.04 Da, RQ-8) were obtained and exhibited high free radical scavenging activity and increased expression of dismutase and catalase genes in cell line. Ibrahim et al. (2018) fractionated camel milk proteins and hydrolyzed them separately using pepsin. Results revealed that antioxidant peptides with molecular weights between 913 to 2351 Da were derived from α-casein and lactoferrin, respectively, thus suggesting that both casein and whey proteins from camel milk have the potential for being utilized as an ingredient in nutraceuticals or functional foods. Kumar et al. (2016b) used commercial proteases namely papain, Alcalase and chymotrypsin to hydrolyze the casein

| Protein Fraction | Camel (g/kg) | Goat (g/kg) | Sheep (g/kg) | Yak (g/kg) | Donkey (g/kg) | Mare (g/kg) |
|------------------|-------------|-------------|--------------|------------|---------------|-------------|
| Total casein     | 22–48       | 23–38       | 41–66        | 21–40      | 6–10          | 8–14        |
| αs1-Casein (%)   | 21          | 4.5–34      | 7–40         | 13–32      | –             | 17–47       |
| αs2-Casein (%)   | 9           | 9–25        | 12–23        | 9–18       | –             | 2           |
| β-Casein (%)     | 65          | 34–64       | 34–62        | 37–51      | –             | 46–79       |
| κ-Casein (%)     | 3–5         | 10–19       | 7–23         | 12–21      | –             | 2–8         |
| γ-Casein (%)     | –           | 5–6         | –            | –          | –             | –           |
| Total whey proteins (g/kg) | 6–10       | 3–12        | 8–16         | 11         | 5–9           | 7–10        |
| α-Lactalbumin (%) | 45–53      | 17–50       | 13–45        | 7–20       | 23–33         | 17–42       |
| β-Lactoglobulin (%) | 34–77      | 28–72       | 50–86        | 30–57      | 17–50         |             |
| Serum albumin (%) | 30–41      | 5–22        | 6            | 7–15       | 6–7           | 3–5         |
| Immunoglobulins (g/kg) | 0.55–0.8 | 0.15–0.5    | 0.5–0.7      | 0.1–0.4    | 1.3           | 0.4–2.5     |
| Lactoferrin (g/kg) | 0.2–0.9 | 0.02–0.3    | 0.7–0.9      | 0.2–0.7    | 0.3           | 0.6–1.3     |
| NPN (% total N)  | 6–11        | 7–12        | 6–9          | 6          | 11–25         | 10–15       |

The table is adapted and modified from (Alichanidis et al. 2016)
fraction of camel milk protein. It was found that the hydrolysate obtained by chymotrypsin had a higher antioxidant activity, while Alcalase and chymotrypsin both yielded peptides with comparable antimicrobial activity. They concluded that the whole milk protein hydrolysate could be more beneficial when used as a nutraceutical or functional food ingredient in comparison to hydrolysates of milk protein fractions. Jrad et al. (2014) had studied the antioxidant properties of camel milk casein hydrolysate using 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) radical cation and concluded that antioxidant activity of camel milk casein was much more efficient after digestion with pepsin and pancreatic enzymes. On similar lines, Kumar et al. (2016a) investigated the antioxidant activity of casein hydrolysate after hydrolysis by Alcalase and papain. They found that both the hydrolysates obtained exhibited a significant increase in 2,2-diphenyl-1-picrylhydrazyl (DPPH), Ferric Reducing Antioxidant Power (FRAP), and ABTS, with an increase in the duration of hydrolysis and degree of hydrolysis. Three novel antioxidant peptides have been isolated from Bactrians camel milk hydrolysate by Wali et al. (2020). All purified and sequenced peptides: RLDG QGRPRVWLGR (TFI-b1), MW: 1665.94; TPDPNDIW LGGIAEPPQVKR (TFI-b2), MW: 2122.13; and VAYSDD-GENWTEYRDQGAVEGK (TFI-b3), MW: 2489.09 exhibited very high antioxidant activity as free radical scavengers.

**ACE inhibitory peptides** Higher proline content in the structure of casein fraction of camel milk is reported to be a contributory factor for better ACE inhibitory and antioxidant activity of hydrolysates obtained from camel milk as compared to the milk from other species (Moslehishad et al. 2013). ACE inhibitory activity of camel milk hydrolysate obtained by in vitro gastrointestinal digestion was studied by Tagliazucchi et al. (2016). They studied the different fractions and found that the strongest ACE inhibitory activity was exhibited by the post-pancreatic < 3 kDa fraction. Sequencing of these fractions yielded 17 peptides known to possess ACE inhibitory activity. In another study by Alhaj (2016), peptides possessing ACE inhibitory activity were identified from fermented camel milk of dromedary species. Camel milk was fermented with two potent bacterial cultures namely, *L. helveticus* and *L. acidophilus*. HPLC-MALDI-TOF analysis showed the presence of ten potent peptides exhibiting ACE-inhibitory activity. Camel milk fermented with *L. helveticus* yielded stronger ACE-inhibitory activity than other strains (*L. acidophilus*). Results of this study also revealed that these peptides were stable up to 15 days of storage. Camel milk protein fractions, namely β-casein and whole casein, were also studied by Salami et al. (2010), and they evaluated the biological activity of these fractions. Results showed that the digestion with pepsin enhanced the ACE-inhibitory activity of the whole as well as β-casein. Therefore, camel milk was suggested to release innate peptides with antihypertensive properties. Mimicking the in vitro gastrointestinal digestion model for digestion of camel milk proteins (whey and casein), it was found that a higher ACE inhibitory activity was achieved following digestion with pepsin (Jrad et al. 2014). Moreover, camel colostrum also exhibited a higher ACE-inhibitory activity following digestion. The study identified 180 peptides with biological activities, out of which 25 peptides were known to be associated with ACE-inhibitory activity. Shuangquan et al. (2008) had also studied the ACE inhibitory activity of fermented skim camel milk. Fermentation of skim camel milk was achieved by culturing with *L. helveticus*130 B4. Peptide sequences exhibiting the strongest antihypertensive activity were derived from κ-casein and it was also demonstrated that inhibitory activity was quite stable after treatment at 100 °C for 20 min. Rahimi et al. (2016) had used proteinase K for the evaluation of ACE inhibitory activity of camel milk casein hydrolysates and results recommended the use of whole camel casein as a substrate for the production of peptides with antihypertensive properties. Soleymanzadeh et al. (2019) had identified a novel ACE inhibitory peptide from fermented camel milk (*Leuconostoc lactis*). Less than 3 kDa ultra filtered fraction with biologically active peptide (MVPPQQR) exhibited ACE-inhibitory activity with IC$_{50}$ value of $1.61 \pm 0.18$ mg/mL.

**Anti-diabetic and Anti-obesity peptides** Novel anti-diabetic and anti-obesity peptides (KDLWDFFKGL, MPSKPLL) were obtained in the hydrolysates of camel milk protein in a study by Mudgil et al. (2018). Nongonierma et al. (2017) identified anti-diabetic peptides with dipeptidyl peptidase 4 (DPP-IV) inhibitory activity, in camel milk protein hydrolysates. Results revealed the presence of potential and novel DPP-IV inhibitory peptides (Leu-Pro-Val-Pro-Gln and Trp-Lys) which were reported to be absent in bovine milk hydrolysates. This indicated the unexplored potential of camel milk as a substrate for diabetes management. Also, Nongonierma et al. (2018) identified nine novel peptides possessing DPP-IV inhibitory activity (FLQY, FQLGASPY, ILDKEGIDY, ILELA, LLQLEAIR, LPVP, LQALHQQQIV, MPVQA, and SPVVPF) upon the hydrolysis of camel milk protein with trypsin. Thus, camel milk was reported to be an important commodity having a role in glycemia regulation. Cholesterol esterase has been reported to be associated with the development of obesity and other related complications. Thus, in an interesting study conducted by Mudgil et al. (2019), novel peptides were isolated from camel milk protein hydrolysate and then evaluated for their inhibition of cholesterol esterase. Results revealed that hydrolysate
obtained by the digestion with papain exhibited the highest degree of hydrolysis. Peptide identification showed three peptides with sequences KFQWGY, SQDWSFY, and YWYPPQ, exhibiting high affinity towards the binding site of cholesterol esterase.

**Antimicrobial peptides** In a study by Algboory and Muhialdin (2018), protein hydrolysates found in fermented camel milk produced using *Lactobacillus plantarum*, exhibited antimicrobial activity against *Staphylococcus* sp., *Shigella*, and *E. coli*. One of the fractions, out of the 14 isolated, yielded 32 low molecular weight peptides and exhibited the strongest antimicrobial activity. This study suggested the utilization of *L. plantarum* as a suitable starter culture for the production of antimicrobial peptides in camel milk-based functional products. Jrad et al. (2014) investigated the antimicrobial properties of camel colostrum as well as camel milk proteins and demonstrated that colostrum and milk both had an inhibitory effect on the growth of *Ecoli* and *L. innocua*. They also showed that the antimicrobial effect was significant even before the digestion of the sample, however, it became pronounced after the samples were subjected to gastric and intestinal proteolytic enzymes. Abu-qatouseh (2019) derived immune proteins and peptides from camel milk and evaluated their efficacy against *Propionibacterium acnes*. It was shown that peptidoglycan recognition proteins exhibited the strongest antimicrobial activity as compared to lactoferrin. Thus, camel milk was suggested to be utilized for the treatment of *Acne vulgaris*.

**Goat milk**

Goat milk has been extensively studied and characterized for their bioactive peptides. They also contain the four main fractions of caseins (αs1-casein, αs2-casein, β-casein, and κ-casein), however, goat casein has been found to undergo a broad range of post-translational modifications leading to the production of a wide variety of the casein molecule (Marletta et al. 2007). Goat milk whey proteins primarily consist of α-lactalbumin and β-lactoglobulin, the latter being significantly higher in concentration than cow’s milk (Moatsou et al. 2005). Various bioactive peptides have been reported to be produced from goat milk and milk products in the past decades. Some of those beneficial properties are reported here as follows:

**Antioxidant peptides** Fermented goat milk has shown the presence of antioxidant peptides more often. In this regard, *Lactobacillus casei L61* was used to ferment the goat milk and the milk was further subjected to isolation and purification of antioxidant peptides (Shu et al. 2018). They proved that these antioxidant peptides were quite stable during simulated in vitro digestibility experiment. Commercial proteases namely, subtilisin and trypsin, were used to produce goat milk microfiltration hydrolysate (De Gobba et al. 2014). It was found that the retentate generated with subtilisin hydrolysis, showed the highest radical scavenging activity, whereas, the permeate had a high iron chelation capacity and formed a large number of secondary lipid oxidation products. The role of non-protein compounds in permeate was highlighted more than the antioxidant activity related peptides. Similarly, antioxidant peptides were identified in goat milk protein fractions by Ahmed et al. (2015). Goat milk proteins were fractionated into casein and whey, which were further digested using pepsin. Peptides generated showed potent DPPH and superoxide quenching activity. MALDI-TOF-MS was further used to identify these peptides and it was found that β-casein and β-lactoglobulin were the major contributors to these antioxidant bioactive peptides. In a study by Li et al. (2013), antioxidant peptides were purified and identified from casein protein fraction of goat milk. Neutral and alkaline proteases were used to produce goat milk casein hydrolysate. They found a significant increase in free radical scavenging and iron chelation capacities with goat milk protein hydrolysate which was attributed to five novel oligopeptides, namely Val-Tyr-Pro-Phe, Phe-Gly-Gly-Met-Ala-His, Phe-Pro-Tyr-Cys-Ala-Pro, Tyr-Val-Pro-Glu-Pro-Phe, and Tyr-Pro-Pro-Tyr-Glu-Thr-Tyr. Antioxidant activity of these peptides were 3.60 to 3.80 times higher than the goat milk casein.

**ACE inhibitory peptides** ACE inhibitory peptides have an immense role in lowering blood pressure or to combat hypertension. Commercial proteases have been studied for ACE inhibitory peptide production from goat milk by Bao et al. (2016). Alcalase was found to be the best enzyme for the production of ACE-inhibitory peptides with 95.31% activity. In another study by Geerlings et al. (2006), subtilisin and Alcalase were used to identify and characterize ACE inhibitory peptides from goat milk. They isolated three novel ACE inhibitory peptides namely, TGIPPN, SLQP, and SQPK, with inhibitory concentrations of 316, 330 and 354 μmol/L, respectively. In the same study, the efficacy of the goat milk protein hydrolysate was evaluated using in vivo models and it was found that the long-term administration of goat milk protein hydrolysate reduced the occurrence of hypertension, cardiac and renal hypertrophy, and renal dysfunction. Espejo-Carpio et al. (2014) produced ACE inhibitory peptides from ultra-filtered goat milk protein hydrolysates (casein fractions). Treatment of ultra-filtered goat milk casein with subtilisin and trypsin exhibited relatively higher ACE inhibitory activity. Besides commercial proteases, purified proteinase has also been studied for its efficacy in
the production of peptides. One such study employed partially purified proteinases of Lactobacillus helveticus PR4 and the hydrolysate was subjected to reversed phase fast protein liquid chromatography for peptide fractionation (Minervini et al. 2003). Fractions with the highest ACE inhibitory activity (β-CN f58–65 and αS2-CN f182–187) were sequenced by mass spectroscopy. Corresponding sequences obtained were LVYFPFGP and TVDQHQ with monoisotopic mass of 888.47 Da and 727.33 Da, respectively.

Bacterial cultures have also been used for the production of ACE inhibitory peptides. Chen et al. (2018) used Lactobacillus plantarum 69 to ferment goat milk and evaluate its potential to generate ACE inhibitory peptides. The generated hydrolysate exhibited 88.91% ACE inhibitory activity; however, when it was further purified by ultrafiltration and RP-HPLC, it showed an ACE inhibitory activity of 91.62%. Another study conducted by Shu et al. (2017) utilized Lactobacillus bulgaricus LB6 for the fermentation of goat milk to increase antihypertensive activity. Results showed an increase in ACE inhibitory activity by 10% (from 75% to around 84.6%). Ibrahim et al. (2017) evaluated the presence of ACE inhibitory peptides separately in casein and whey fractions of goat milk. They found that pepsin generated hydrolysates of whey and casein demonstrated significantly higher ACE inhibitory activities as compared to the undigested proteins. Furthermore, they identified three potent ACE inhibitory peptides namely, PEQSLACQCL from β-lactoglobulin (residues 113–122), QSLVYP FTGPI from β-casein (residues 56–66), and ARHPHPHLF SFM from κ-casein (residues 96–106), which exhibited significantly higher ACE inhibitory activity than a commercial antihypertensive drug, captopril. In another study conducted by Aslam et al. (2018), goat milk proteins were fermented with Lactobacillus helveticus -cicc 22,171 and further hydrolyzed to elucidate the structure and amino acid sequences with mass spectrometry. The results revealed that the peptides, VLPVPQKAVPQ and INNQFLPYPY, after treating the goat milk casein with trypsin and chymotrypsin. They have used two-dimensional silica-thin layer chromatography technique for their isolation and identification.

**Antimicrobial peptides** The commercial protease, Alcalase, was used to hydrolyze whey protein fraction of goat milk (Osman et al. 2016). Fractions with the highest degree of hydrolysis were fractionated further and evaluated for their antibacterial activity by disc diffusion method. Fractions eluted by size exclusion chromatography showed antibacterial activity against E. coli with a minimum inhibitory concentration (MIC) of 0.09 mg/mL and against B. cereus (MIC: 0.03 mg/mL). The study concluded with the potential of goat milk whey hydrolysate to control undesirable bacteria in food products. Fungal proteases, from Aspergillus oryzae and Aspergillus flavipes, have also been used to hydrolyze goat milk, which was further evaluated for their potential role in antimicrobial activity (Zanutto-Elgui et al. 2019). Results revealed that the generated peptides exhibited antimicrobial activity against all tested bacteria and fungi. Goat milk whey fraction has also been evaluated for its antifungal and antimycotoxigenic activity on Penicillium spp (Luz et al. 2020). Twenty seven peptides were identified from α-lactalbumin, β-lactoglobulin, κ-casein and lactoferrin, which exhibited fungal growth inhibition and Minimum Inhibitory Concentration (MIC) of 3.9–62.5 g hydrolysate/L. In another study by Lestari and Suyata (2019), goat milk from Etawa breed was hydrolysed with crude extract of bromelain enzyme (from pineapple). The hydrolysate was tested for its antibacterial activity (against E. coli and S. aureus) and the results demonstrated significantly higher antibacterial activity compared to the non-digested control. Similarly, Esmaeipour et al. (2016) used trypsin and ficin enzymes to evaluate the efficacy of goat milk casein hydrolysate and reported that one of the fractions (F14) possessed a very high antibacterial activity against E.coli and B. cereus.

**Sheep**
Sheep milk consists of high protein content (around 5.8% on average), however, this varies among different breeds of sheep, usually influenced by genetic and environmental factors (Recio et al. 2009). Sheep milk protein is characterized by 76–83% of total casein and 17–24% of total whey proteins (Moatsou et al. 2005). The casein protein is further relatively distributed as 12–16.4% of αs2-casein, 33.9–39.9% of αs1-casein, 37–42.3% of β-casein, and 9.1–10.8% of κ-casein (Moatsou et al. 2004). Sheep milk protein hydrolysates have been shown to possess multiple health beneficial factors as follows:
Antioxidant peptides: Hydrolysis of sheep milk sodium caseinate with *Bacillus* sp. P7 protease generated peptides with an antioxidant activity which was higher than the intact protein (Corrêa et al. 2011). Sequential hydrolysis of the sheep casein protein with pepsin, trypsin, and chymotrypsin produced hydrolysates with high antioxidant activity, and this effect was more pronounced with κ-casein. The most potent peptide found in the κ-casein hydrolysate was HPHPHLSF, among eleven other peptides identified, showing the antioxidant activity. The isolated peptide HPHPHLSF demonstrated lipid peroxidation inhibition activity similar to the synthetic antioxidant Butylated hydroxytoluene (BHT). The strong antioxidant activity of the peptide was mainly attributed to the presence of high histidine and leucine content in the peptide sequence, which is known for its oxidation inhibition properties. Besides, even proline has been known for its antioxidant properties. Thus, the peptide HPHPHLSF could potentially be used as a natural antioxidant replacing the synthetic ones (Gómez-Ruiz et al. 2008).

ACE inhibitory peptides: ACE inhibitory peptides were generated from sheep sodium caseinate hydrolysis via *Bacillus* sp. P7 protease. However, 2 h hydrolysis produced the most active peptides while an increase in the hydrolysis time decreased the ACE inhibitory activity (Corrêa et al. 2011). Sheep casein hydrolyzed by *Lactobacillus helveticus* PR4 protease generated ACE inhibitory peptides derived from α₂-casein (residues 182–185) and α₁-casein (residues 1–6) (Minervini et al. 2003). Trypsin hydrolysis of sheep β-lactoglobulin (both A and B variants mixture) generated ACE inhibitory peptides from the N-terminal of the protein. Among those peptides, the more hydrophilic ones were shown to possess higher ACE inhibitory activity (Recio et al. 2009).

Antimicrobial peptides: *Bacillus* sp. P7 derived protease hydrolysis of sheep caseinate produced hydrolysates which demonstrated antimicrobial activities against *Cornebacterium fimii*, *Bacillus cereus*, *Aspergillus fumigatus*, and *Penicillium expansum* (Corrêa et al. 2011). Peptidic hydrolysis of the αs2-casein generated four antibacterial peptides from the casein protein corresponding to the amino acid residues 165–181 (LKKISQYQQFKAWSQY), 165–170 (LKKISQ), 203–208 (PYVRYL), and 184–208 (VDHQKAMKPTQPHTNAPYVRYL). These peptides were shown to be effective against various Gram-positive and Gram-negative bacteria. Among the four peptides, the most potent one was derived from amino acids 165–180 (López-Expósito et al. 2006). Sheep α-lactalbumin and β-lactoglobulin hydrolysis with pepsin generated hydrolysates capable of exhibiting dose-dependent antibacterial activity against *Bacillus subtilis*, *Escherichia coli*, and *Staphylococcus aureus* (Elzahar et al. 2004).

Antithrombic peptides: Sheep casein glycomacropeptide (CMP) has been demonstrated to possess antiplatelet aggregation properties and this activity was further shown to increase with trypsin hydrolysis. Trypsin hydrolysis of sheep CMP released two peptides derived from κ-casein (amino acids 163–171 and 165–171) which had high antithrombotic activities (Qian et al. 1995).

Yak: Yak milk consists of high protein content (46.2–58.4 g/L) out of which casein constitutes almost about 40.2 g/L on an average. It is also rich in milk fat (6.7%) and non-fat solids (11%). Yak milk products are a major ingredient in the Mongolian indigenous diet (Ochirkhuyag et al. 1997).

In a study by Jiang et al. (2007), yak milk casein was hydrolyzed by six different protease enzymes. The hydrolysates with the highest ACE inhibitory activity were obtained from the hydrolysis with Neutrase enzyme with an IC₅₀ value of 0.38 mg/mL. Five peptides were identified from this hydrolysate which were shown to possess the ACE inhibitory activity: LQNIPPL (β-casein, residues 70–77), YQKFPQY (α₂-casein, residues 89–95), LPYYPY (κ-casein, residues 56–61), SKVLPVPQK (β-casein, residues 168–176), and FLPYPYY (κ-casein, residues 55–61). All these five peptides were identical with peptides found in cow’s milk casein and possessed ACE-inhibitory activities. Furthermore, for four out of the five peptides, the C-terminus was occupied by a hydrophobic amino acid, which is a characteristic feature of known ACE inhibitory peptides (Jiang et al. 2007).

In a study by Mao et al. (2007a, 2007b), hydrolysates obtained via Alcalase hydrolysis of yak milk casein were shown to modulate the differentiation of T-helper cells (Th) along with shifting the Th1/Th2 balance towards Th1-dominant phenotype. Thus, it was suggested that yak milk-derived hydrolysates could potentially help in cell-mediated immune diseases (Mao et al. 2007a, 2007b). The Alcalase derived hydrolysates were also found to suppress tumor cells (Mao et al. 2005). In another study, which tested the role of several different enzymes as well as different hydrolysis times in the generation of bioactive hydrolysates, it was shown that yak casein hydrolysates obtained from trypsin and Alcalase hydrolysis yielded peptides with higher DPPH-scavenging activities, as compared to flavozyme, papain, and peptic hydrolysates. Furthermore, the 7 h long hydrolysis with Alcalase had the highest DPPH-scavenging activity, compared to shorter hydrolysis periods (Mao et al. 2011).
Alcalase hydrolysis of the yak milk casein also led to the generation of ACE inhibitory hydrolysates. The hydrolysate was further separated into different molecular-sized fractions via membrane ultrafiltration. The highest ACE inhibitory activity was shown by the 6 Da fractions amongst all the other fractions of the hydrolysate. Two novel peptides involved in the ACE inhibitory activity were identified in the 6 Da fractions, which were, PLPLL (β-casein, amino acid residues 136–140) and PPEIN (κ-casein, amino acid residues 156–160). The IC50 and molecular weight of the two peptides were 566.4 and 550 Da, and 0.25 ± 0.01 and 0.29 ± 0.01 mg/mL, respectively (Mao et al. 2007a, 2007b).

Alcalase derived yak casein hydrolysates have also been shown to possess immunomodulatory and antioxidant activities, as the hydrolysates have been effective in reducing the expressions of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and IL-6, as well as reducing free radicals of DPPH, hydrogen peroxide, and superoxide (Wang et al. 2011). However, the peptides in these hydrolysates have not been separated and characterized. Moreover, Wang et al. showed that yak casein hydrolysates were capable of mineral binding as they could bind ferrous and zinc ions to form soluble complexes in simulated intestinal conditions (Wang et al. 2011). The major binding sites consisted of amide and carboxylate groups; however, specific peptides have not been identified yet.

In a study by Pei et al. (2017), waste yak milk, produced as a by-product during production of yak butter, was hydrolyzed by pepsin, and the hydrolysates produced were found to possess antimicrobial activity. On further purification and analysis, two peptides were identified in the hydrolysate responsible for the antimicrobial activity, namely, RVMFKWA and KVISMIL. These peptides exhibited antimicrobial activities against bacteria such as E. coli, Listeria innocua, Salmonella paratyphi, and Enterobacter cloacae, as well as against certain fungi (Pei et al. 2017).

Another recent study by Lin et al. (2018) highlights an in silico proteolysis approach for the release of bioactive peptides with ACE-inhibitory activity from yak milk casein, using single or combined enzymes. The study identified several peptides with ACE inhibitory properties such as LPLPLL, KYIPIQ, and FPPGIPPN. Furthermore, their cytotoxicity was also determined through ToxinPred (online toxin prediction tool), to find that the peptides identified were non-toxic (Lin et al. 2018). This study could potentially serve as a guide for the actual yak milk protein hydrolysis and the identification of bioactive peptides.

Mare

Mare’s (Equine) milk has been long used for its unique therapeutic and nutritive values in the southern states of former Soviet Union and Mongolia, which is currently also gaining acclamations in parts of Europe (Sheng and Fang 2009). Fermented mare milk, also known as Koumiss, has been used as a curative for cardiovascular and digestive disorders in Mongolia and Russia (Lozovich 1995).

Some of the qualitative and quantitative characteristics of mare milk which has been reported (Miranda et al. 2004; Uniacke-Lowe et al. 2010) are as follows:

- Mare milk contains about 2.7% of total proteins, out of which 55% is casein, while the rest is composed of β-lactoglobulin, α-lactalbumin, whey proteins, immunoglobulins, and lysozyme.
- Proteins in mare milk are rapidly hydrolyzed by human gastrointestinal enzymes as compared to other popular milk proteins such as cow, camel, goat, and human milk proteins.
- Casein fraction of mare milk is considerably made up of β-casein, followed by αs1-casein, αs2-casein, and κ-casein.
- The αs1-casein in mare milk is composed of 205 amino acids with 6 phosphorylation sites, and 5 of those sites are so close to each other that they are considered as a probable source of bioactive peptides.
- The β-casein of mare milk consists of 226 amino acids with 7 potential phosphorylation sites at the C-terminal.

Although very limited research is available on the bioactive peptides released from mare milk, koumiss (fermented mare milk) has been reported to have ACE inhibitory activity (IC50 52.5 ± 2.9 mg/mL). The ACE inhibitors found in koumiss are reported to be true inhibitors or the prodrug type inhibitors, based on the hydrolysis pattern of the gastrointestinal enzymes (Chen et al. 2010). The fraction with the highest ACE-inhibitory activity (IC50 80.11 ± 2.13 mg/mL) was < 3 kDa in molecular weight and 21 peptides were separated from the fraction which showed variable ACE-inhibitory activity. There were 4 most potent peptides identified with ACE-inhibitory activity among 21 other peptides. The only ACE-inhibitory peptide found in koumiss was derived from the peptide P1 (β-casein, amino acids 217–241) (Chen et al. 2010). Protein P2 originated from cytochrome c, whereas proteins P3 and P4 were of unknown origin, probably of microbial origin. The unique feature of P1 ACE-inhibitory peptide is its length, which is 27 amino acids residues long, but still possesses high ACE-inhibitory activity. In general, such high activities are a characteristic of smaller peptides (2–10 amino acid residues) (Ricci et al. 2010).

In another study by Kusumaningtyas et al. (2018), hydrolysis of the Sumbawa mare milk protein via Bacillus
**Bioactive peptides derived from milk products of minor dairy species**

Milk-based products hold an important role in the daily diet of people worldwide. Rearing of minor dairy species for production of milk is limited; however, different dairy products are being manufactured to meet the local requirements. Fermentation-based dairy products like cheese, fermented milk, yoghurt are highly popular. The data related to their preparation and physico-chemical properties are widely available due to the rapidly increasing interest in these products. However, limited studies have been carried out on bioactive properties of dairy products obtained from minor dairy species (Table 4).

**Cheese**

The type and concentration of bioactive peptides in cheeses may vary with thermal treatment of milk, type of starter, manufacturing conditions, ripening stage, curd scalding temperature, ripening stage, and rennet origin (Kocak et al. 2020; Meira et al. 2012; Silva et al. 2006). Among minor species, sheep and goat milk were widely explored for preparation of different varieties of cheeses. β-casein-hydrolyzed fragments f(201–204) (VRGP), f(47–51) (DKIHP), and f(47–52) (DKIHPF), in 60 days old Spanish goat milk cheese, possessed ACE inhibitory activity (Gómez-Ruiz et al. 2006). In freeze-dried water-soluble extracts of sheep and goat milk cheese peptide, sequences VPKVK, YQEP, and YQEPVLGP, from native β-casein exhibited antioxidant and ACE inhibitory activity with higher extent of bioactivity in goat milk cheese (Silva et al. 2006). In goat milk cheese, ethanol soluble and insoluble nitrogen fractions showed ACE inhibitory activity owing to the small and medium sized peptides. Similarly, acid soluble and non-protein nitrogen fractions, consisting of medium and short chain peptides, possessed antioxidant activity (Hernández-Galán et al. 2017). Water soluble extracts of goat milk-based Tulum cheese, not only showed antioxidant activity and iron chelating ability, but also exhibited antimicrobial activity against *Salmonella typhimurium* ATCC 14028 on the 90th day of ripening (Öztürk and Akin 2018). The incorporation of adjunct cultures (*Lactobacillus casei*, *Lactobacillus plantarum*, and *Lactobacillus bulgaricus*) with a starter mix (*Lactococcus lactis subsp lacidis* and *Lactococcus lactis subsp cremoris*), for the preparation of goat milk brined cheese, contributed to the higher concentration of ACE inhibitory and antioxidant activity peptides along with other water-soluble nitrogenous compounds. These differences could be attributed to strain-dependent peptidase activity of adjuncts. However, even all the samples, irrespective of type of culture mix,
| Species | Function | Peptide Sequence | Activity | Reference |
|---------|----------|------------------|----------|-----------|
| Goat    | ACE-inhibitory activity | LVYPFPGP (β-CN, f58–65) TVDQHQ (αS2-CN, f182–187) TGPIP (β-CN, f78–83) SLQ (β-CN, f84–87) SQPK (β-CN, f181–184) | 95.31% | (Bao et al. 2016) |
|         |           | PEQSLACQCL (β-Lg, residues 113–122) QSLVYPFFGP (β-CN, residues 56–66) ARHPHPHLSFM (κ-CN, residues 96–106) | IC₅₀ 316–354 μmol/L | (Geerlings et al. 2006) |
|         |           | ND (Minervini et al. 2003) | 88.91% | (Chen et al. 2018) |
|         |           | ND (Espejo-Carpio et al. 2014) | IC₅₀ 4.45 μM (whey fraction) | (Ibrahim et al. 2017) |
|         |          | PEQSLACQCL (β-CN, f78–83) SLPQ (β-CN, f84–87) SQPK (β-CN, f181–184) | IC₅₀ 4.27 μM (Casein fraction) | (Ibrahim et al. 2017) |
|         |          | ND (Geerlings et al. 2006) | IC₅₀ 316–354 μmol/L | (Geerlings et al. 2006) |
| Anti-diabetic activity | Anti-diabetic activity | SDIPNPNSGE (αS1-casein, f195–204) NPWDQVKR (αS2-casein, f123–130) SLSSSEESITH (β-casein, B0–40) QEPVLQGVPKPPP (β-casein, f207–219) | ND | (Gong et al. 2020) |
| DPP-IV inhibitory activity | DPP-IV inhibitory activity | MHQPPQPL (β-CN, f144–151) SPTVMPQTSVL (β-CN, f152–163) VMFPQOSVL (β-CN, f155–163) INNQFLPY (κ-CN, f51–60) | ND | (Zhang et al. 2015) |
| Anti-oxidant activity | Anti-oxidant activity | ND | 88.01 ± 0.69% | (Shu et al. 2018) |
| Anti-oxidant activity | Anti-oxidant activity | ND | ABTS (SC₅₀ 4 μg/mL) Iron chelation activity IC₅₀ 65 μg/mL | (De Gobba et al. 2014) |
| Anti-oxidant activity | Anti-oxidant activity | ND | ABTS (SC₅₀ 4 μg/mL) Iron chelation activity IC₅₀ 65 μg/mL | (De Gobba et al. 2014) |
| Anti-oxidant activity | Anti-oxidant activity | LHSMKGANPAHQKQP (αS1-CN, f120–134) PLRYVEELKP (β-Lg, f 38–48) PEQSLACQCL (β-Lg, f 113–122) SDIPNPQNSGKTTMPL (αS1-CN, f 180–198) SLTLTDVEKLHLPL (β-CN, f 124–137) | ND | (Ahmed et al. 2015) |
| Anti-microbial activity | Anti-microbial activity | ND | Highest activity against E. coli and B. cereus | (Esmæilipour et al. 2016) |
| Anti-bacterial activity | Anti-bacterial activity | ND | Highest Activity against E. coli and S. aureus | (Lestari and Suyata 2019) |
| Anti-fungal activity | Anti-fungal activity | ND | Minimum inhibitory activity (3.9–625 g/L) minimum fungicidal concentration (15.8–250 g/L) | (Luz et al. 2020) |
| ACE-inhibitory activity | ACE-inhibitory activity | ND | IC₅₀ value of 218.50 μg/mL | (Espejo-Carpio et al. 2014) |
| Anti-microbial activity | Anti-microbial activity | FHFKICMKMKYL | ND | (Tormazou et al. 2019) |
| Species | Function | Peptide Sequence | Activity | Reference |
|---------|----------|-----------------|----------|-----------|
| ACE-inhibitory activity | VLPVPQAVQP, VLPVPQAVQP, TQTPYVVPFLQPEMGVPKVE | ND | (Aslam et al. 2018) |
| Anti-fungal activity | QSQQYQK (d52-CN, f182–189), FASNPQYK (d52-CN, f189–197) | Against Aspergillus oryzae and Aspergillus flavipes | (Zanutto-Elgui et al. 2019) |
| Camel Milk | Anti-oxidant activity | LEEQQQTEDEQQDQL (LL-15), YLEELHRLNAQ (YY-11), RGLHPQVP (RQ-8) | ND | (Homayouni-Tabrizi et al. 2017) |
| Anti-oxidant activity | ATTLEGKLVEL (Lactophorin, f79 to 89), KADAVLTDGQL (Lactoferrin, f53 to 63), KFGRKPGSFRQL (Lactoferrin, f277 to 288) | ND | (Ibrahim et al. 2018) |
| Anti-microbial activity | RYMESPOFTSDPAQ (Lactophorin, f14), FRNITATSEETRE (Lactophorin, f14), QMVPPQQR (BCN, f14), IASEDGGKTDMPPQ (α-S1 CN, f14), SSFRNITATSEEE (α-S1 CN, f14) | Against Staphylococcus faecalis, Shigella dysenteriae, Staphylococcus aureus and E. coli. | (Alqaboory and Muhiadin 2018) |
| ACE-inhibitory activity | LLSQFVKLPQ (BCN, f178–191), KVLPPQVMPYVPQ (BCN, f185–198), TLDDLHLPLL (BCN, f144–155) | ND | (Alhaj 2017) |
| ACE-inhibitory activity | DLDDLHLPLL, LTDLDDLHLPLL, TDLDDLHLPLL, TDLDDLHLPLL | ND | (Jrad et al. 2014) |
| Anti-oxidant activity | ND | 91.28% inhibition; 32.25% DPPH radical scavenging activity; | (Kumar et al. 2016a, 2016b) |
| Anti-oxidant activity | ND | 1.6 μmol TEAC/mg protein and 0.25 μmol TEAC/μmol eq. NH₂ | (Jrad et al. 2014) |
| ACE-inhibitory activity | ND | 2.223 to 3.930 mg/mL | (Moslehi-shad et al. 2013) |
| Anti-inflammatory activity | ND | ID₅₀ 0.2 mg/mL | (Abu-qatouseh 2019) |
| Anti-obesity | KDLDWDFKQL MP5KPPLL | ND | (Mudgil et al. 2018) |
| Cholesterol esterase inhibitory activity | KFQWGY SQDWFSY YWYPQQ | ND | (Mudgil et al. 2018) |
| DPP-IV inhibitory activity | FQOY (αs2-CN, f71–74), FQLOGASPY (αs1-CN, f68–175), ILDKEGIDY (α-La, f95–103), ILEEAL (αs1-CN, f28–32), LLLFQAIR (αs1-CN, f108–115), LQV (BC-CN, f172–175), LQALHOGQW (αs2-CN, f75–84), MPVQA (BC-CN, f186–190) | LPVP IC₅₀ 870, MPVQA IC₅₀ 933 μM | (Nongonierma et al. 2018) |
| Species | Function | Peptide Sequence | Activity | Reference |
|---------|----------|-----------------|----------|-----------|
|         | ACE-inhibitory activity | Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp (κ-CN, f 107–115) | IC₅₀ = 19.9 μmol/L | Shuangquan et al. 2008 |
|         | ACE-inhibitory activity | ND | IC₅₀ = 73 μg/mL | Rahimi et al. 2016 |
|         | Anti-oxidant and ACE-inhibitory activity | MVPYPQR (β-CN, f 193–199) | IC₅₀ > 1000 mM TEAC/mg peptide ACE-I | Soleymanzadeh et al. 2019 |
|         | Anti-oxidant activity | VAHIPS (αs2-CN, f 7–32) | IC₅₀ 4 = 30 μmol/L | Tagliazucchi et al. 2016 |
|         | Anti-oxidant activity | RLDGQGRPRWRLGR (TFI-b1), TPDIDMLGGLGAPQKR (TFI-b2), VAYSDDGWMTEDQGAVQGK (TFI-b3) | IC₅₀ DPPH assay 1.9, 1.2 and 0.6 mg/mL, ABTS assay 2.4, 1.8 and 0.9 mg/mL | Wall et al. 2020 |
| Sheep   | ACE-inhibitory | PYVRYL (αs2-CN, f 203–208) | IC₅₀ 2.4 μM | Gómez-Ruiz et al. 2007 |
|         | ACE-inhibitory | LKKISQ (αs2-CN, f 165–170) | IC₅₀ 2.6 μM | (BEG et al. 1985) |
|         | ACE-inhibitory | VRYL (αs2-CN, f 205–208) | IC₅₀ 24.1 μM | (Qian et al. 1995) |
|         | ACE-inhibitory | YPIQY (κ-CN, f 25–30) | IC₅₀ 10 μM | (Manso and López-Fandiño 2003) |
|         | ACE-inhibitory | EKDERF (κ-CN, f 12–17) | IC₅₀ 14.3 μM | Papadimitriou et al. 2007 |
|         | ACE-inhibitory | IAK (κ-CN, f 22–24) | IC₅₀ 15.7 μM | (Girardet et al. 2000) |
|         | ACE-inhibitory | LPYPY (κ-CN, f 56–60) | IC₅₀ 28.9 μM | (Papadimitriou et al. 2007) |
|         | Anti-oxidant | MAIPPK (Casein macropeptide, f106–111), MAIPKK (Casein macropeptide, f106–112) | – | |
|         | Anti-oxidant | LOKW (β-LG, f 58–61) | IC₅₀ 3.5 μM | Girardet et al. 2000 |
|         | Anti-oxidant | LLF (β-LG, f 103–105) | IC₅₀ 82.4 μM | (Papadimitriou et al. 2007) |
|         | Anti-oxidant | ALPMHMR (β-LG, f 142–148) | IC₅₀ 62.6 μM | (Gómez-Ruiz et al. 2008) |
|         | Anti-oxidant | IVTQTMK (β-LG, f 1–8) | IC₅₀ 70.8 μM | (Rizzello et al. 2005) |
|         | Anti-oxidant | IDALNENK (β-LG, f 84–91) | IC₅₀ 71.2 μM | (Gómez-Ruiz et al. 2008) |
| Yak     | ACE-inhibitory | HPHPHLSF (κ-CN, f 98–105) | Potent inhibitor of linoleic acid oxidation | |
|         | Anti-microbial | VMFPPQSL (β-CN, f 155–163) and WAPPEV (αs1-CN, f 24–31) | Active against gram-positive and gram-negative bacterial species | |
| Mare    | ACE-inhibitory | PPEIN (κ-CN, f 156–160) | IC₅₀ 290 μM | (Jiang et al. 2007) |
|         | ACE-inhibitory | PLPLL (β-CN, f 136–140) | IC₅₀ 250 μM | |
|         | ACE-inhibitory | YQKFPQY (αs2-CN, f 89–95), LQNIPPL (β-CN, f 70–77), SKVLPAPQK (β-CN, f 168–176), LPYPY (κ-CN, f 56–61), FLPYPY (κ-CN, f 55–61) | IC₅₀ 380 μM (highest activity) | |
|         | ACE-inhibitory | YQPRLGTPGELDPATQPIAVHPNPVIV (β-CN, f 217–241) | IC₅₀ 14.53 μM | (Chen et al. 2010) |
| Species       | Function                               | Peptide Sequence                          | Activity | Reference                                      |
|--------------|----------------------------------------|-------------------------------------------|----------|-----------------------------------------------|
| Donkey milk  | Anti-oxidant activity and ACE-inhibitory activity | PKDLREN (CPN1, f 144–150)                 | IC_{50} 9.82 μM | ND (Aspri et al. 2018)                         |
|              |                                        | LLLAUILL                                   | IC_{50} 5.19 μM |                                              |
|              |                                        | NHNRMRMMDHVH                               | IC_{50} 13.42 μM |                                              |
|              | Anti-oxidant activity                   | LNVSETVES (β-CN)                          | ND       | (Aspri et al. 2018)                           |
|              | Anti-oxidant activity                   | GENRLPAHL (β-CN)                          | ND       | (Bidasolo et al. 2012)                        |
|              | Anti-oxidant activity                   | IOPTMQHIOPOG (β-CN)                       | ND       | (Zenezini Chiozzi et al. 2016)                |
|              | Anti-oxidant activity                   | ENSEKTDIIP (αs1-CN)                       | ND       | (Tidona et al. 2011)                         |
|              | Anti-oxidant activity                   | MGSTBFEE (αs2-CN)                         | ND       |                                              |
|              | Anti-oxidant activity                   | IELSDEEKKNY (αs2-CN)                      | ND       |                                              |
|              | Anti-oxidant activity                   | IPQTMQDLDL (β-Lg)                         | ND       |                                              |
|              | Anti-oxidant activity                   | QVNGGQAHHSV (β-Lg)                        | ND       |                                              |
|              | Anti-oxidant activity                   | AMAASDSSL (β-Lg)                          | ND       |                                              |
|              | Anti-oxidant activity                   | DSESALPVRV (β-Lg)                         | ND       |                                              |
|              | ACE-inhibitory activity                 | VAPFPQPWP (β-CN, f 176–185)               | ND       | (Bidasolo et al. 2012)                       |
|              | ACE-inhibitory activity                 | REWFTFLK                                  | ND       | (Zenezini Chiozzi et al. 2016)                |
|              | Anti-microbial activity                 | WFTFLKAGGQGKDMWR                          | ND       | (Tidona et al. 2011)                         |
|              | Anti-microbial activity                 | GQGAKDMWR                                  | ND       |                                              |

ND = Not defined
| Product                        | Peptide                     | Function                       | Activity                          | References                          |
|-------------------------------|-----------------------------|--------------------------------|-----------------------------------|-------------------------------------|
| **Cheese**                    |                             |                                |                                   |                                     |
| Sheep milk cheese-like system| Val-Pro-Lys-Val-Lys         | ACE-inhibitory, Antioxidant    | 93.75 ± 0.06 IC₅₀ µg/mL, 0.079 ± 0.15 IC₅₀ µg/mL | (Silva et al. 2006)                |
|                               | Tyr-Gln-Glu-Pro             | ACE-inhibitory, Antioxidant    | 169.86 ± 0.10 IC₅₀ µg/mL, 0.102 ± 0.10 IC₅₀ µg/mL |                                     |
| Goat milk cheese-like system  | Tyr-Gln-Glu-Pro             | ACE-inhibitory, Antioxidant    | 689.40 ± 0.18 IC₅₀ µg/mL, 0.072 ± 0.06 IC₅₀ µg/mL |                                     |
|                               | Arg-Pro-Lys-His-Pro-Ile-Lys-His-# | ACE-inhibitory                  | 892.83 ± 0.11 IC₅₀ µg/mL          |                                     |
| **Sheep Milk cheese**         |                             |                                |                                   |                                     |
|                               | Identified in Roquefort type cheese | ACE inhibitory expressed as ABTS (%) scavenging rate | 32.71 ± 1.8 IC₅₀ µg/mL            | (Meira et al. 2012)                |
| **Feta**                      |                             |                                |                                   |                                     |
|                               | WMHPQPQPQPLPTWFMPPQSVL (β-CN f(158–178)) | ACE inhibitory, Antioxidant activity | 67.21 ± 0.1 IC₅₀ µg/mL            |                                     |
| **Pecorino Toscano**          |                             |                                |                                   |                                     |
|                               | MHQPPQPQPLPTWFMPPQSVL (β-CN f(159–178)) | ACE inhibitory, Antioxidant activity | 87.46 ± 0.2 IC₅₀ µg/mL            |                                     |
| **Roquefort**                 |                             |                                |                                   |                                     |
|                               | MHQPPQPQPLPTWFMPPQSVL (β-CN f(159–178)) | ACE inhibitory, Antioxidant activity | 74.96 ± 1.6 IC₅₀ µg/mL            |                                     |
| **Pecorino Sardo**            |                             |                                |                                   |                                     |
|                               | HQQPPQPQPLPTWFMPPQSVL (β-CN f(160–178)) | ACE inhibitory, Antioxidant activity | 67.71 ± 3.2 IC₅₀ µg/mL            |                                     |
| **Carrillano**                |                             |                                |                                   |                                     |
|                               | YQEPVLGVRVRVFPI (β-CN f(206–220)) | ACE inhibitory, Antioxidant activity | 62.59%                           | (Koca et al. 2020)                 |
|                               | QEPVLGVRVRVFPL (β-CN f(207–222)) | ACE inhibitory, Antioxidant activity | ND                               | (Hernández-Galán et al. 2017)      |
|                               | QEPVLGVRVRVFPI (β-CN f(207–220)) | ACE inhibitory, Antioxidant activity | ND                               | (Öztürk and Akin 2018)             |
|                               | PVLGVRVRVFPL (β-CN f(209–220)) | ACE inhibitory, Antioxidant activity | ND                               |                                     |
|                               | LGVRVRVRVFPI (β-CN f(211–220)) | ACE inhibitory, Antioxidant activity | ND                               |                                     |
|                               | TDAPFSDDPPNPQGKSGL (αs1-CN f(189–208)) | ACE inhibitory, Antioxidant activity | 113.1 µM                          | (Gómez-Ruiz et al. 2006)           |
|                               | DPPNPQGKSGL (αs1-CN f(196–214)) | ACE inhibitory, Antioxidant activity | 2419.4 µM                         |                                     |
|                               | IPNPKSENSGKT (αs1-CN f(197–210)) | ACE inhibitory, Antioxidant activity | ND                               |                                     |
|                               | NAGPTTTYVR (αs2-CN f(31–141)) | ACE inhibitory, Antioxidant activity | ND                               |                                     |
|                               | YQPPMLNPVQSDQR (αs2-CN f(116–130)) | ACE inhibitory, Antioxidant activity | 74.96 ± 1.6 IC₅₀ µg/mL            |                                     |
|                               | YQPPMLNPVQSDQR (αs2-CN f(118–130)) | ACE inhibitory, Antioxidant activity | 74.96 ± 1.6 IC₅₀ µg/mL            |                                     |
|                               | GPVPMLNPVQSDQR (αs2-CN f(118–130)) | ACE inhibitory, Antioxidant activity | 74.96 ± 1.6 IC₅₀ µg/mL            |                                     |
|                               | YQPPMLNPVQSDQR (αs2-CN f(121–130)) | ACE inhibitory, Antioxidant activity | 74.96 ± 1.6 IC₅₀ µg/mL            |                                     |
| **White brined goat milk cheese** |                             |                                |                                   |                                     |
|                               | ND                           | ACE inhibitory activity       | 62.59%                            | (Koca et al. 2020)                 |
| **Fresh goat milk cheese**    | ND                           | Antioxidant and ACE inhibitory activity | ND                               |                                     |
| **Goat milk Tulum cheese**    | ND                           | Antioxidant, Mineral binding and antibacterial activity against Salmonella typhimurium ATCC 14028 | ND                               |                                     |
| **Cabrales cheese (Cow + sheep + Goat milk)** | DKKHPF (β-CN f(47–51)) | ACE inhibitory                  | 113.1 µM                          | (Gómez-Ruiz et al. 2006)           |
| **Idiazabal cheese (Sheep milk)** | DKKHPF (β-CN f(47–52)) | ACE inhibitory                  | 2419.4 µM                         |                                     |
| **Mandhego cheese (Sheep milk)** |                             |                                |                                   |                                     |
| **White brined goat cheese**  | RPKHPKHQQQLPQVLENMLL (αs₁ f(1–20)) | Immunepeptide                  | ND                               | (Atanasova et al. 2020)            |
| **Sheep milk cheese**         | LKKISQRA (αs₂ f(165–169))   | Antibacterial                  | ND                               |                                     |
| **Yoghurt**                   |                             |                                |                                   |                                     |
| **Goat milk**                 | ND                           | DPPH scavenging activity       | 39.0 ± 1.0%                       | (Sultan and others 2017)           |
|                               | ND                           |                                | 39.0 ± 1.0%                       | (Sultan et al. 2017)               |
### Table 4: Bioactive peptides derived from milk products of minor dairy species (Continued)

| Product                                      | Peptide Function       | Activity                        | References                                      |
|----------------------------------------------|------------------------|---------------------------------|-------------------------------------------------|
| Sheep milk                                   | ND                     | Antioxidant activity            | 40.3 ± 1.1%                                     | (Guha et al. 2021) |
| Fermented camel milk yoghurt                 | ND                     | ACE inhibitory                  | 113–200                                         | (Alhaj et al. 2018) |
| Fermented camel milk (Chal)                  | ND                     | Antimicrobial activity          | 70–133                                          | (Soleymanzadeh et al. 2016) |
| Camel milk heated at 80 °C/30 min prior to fermentation | ND                     | DPPH activity                   | 57.90 ± 4.59 μM                                  | (Abd Elhamid and Merwe 2017) |
| Fermented camel milk                          | Total 32 peptides      | Antimicrobial activity          | 20.0 and 16.0%, respectively                     | (Algboory and Muhaidin 2018) |
| Goat milk yoghurt                            | AHTPDB                 | Anti-hypertensive               | ND                                              | (Parmar et al. 2020) |
| Goat milk yoghurt                            | Casein fractions       | Antioxidant activity            | ND                                              | (Haskito et al. 2020) |
| Donkey milk fermented with Enterococcus fæciæ DM33 | ND                     | Antioxidant                     | 350 ± 0.01                                       | (Aspri et al. 2018) |
| Fermented mare milk                          | ND                     | ACE inhibitory                  | 70.9–74.5%                                      | (Wang et al. 2015) |
| Sheep milk yoghurt                           | PWNPFLQ (β-CN f(96–104)) | Antihypertensive               | ND                                              | (Dabiel et al. 2018) |
| Greek sheep milk yoghurt                     | YPVEPFTE (β-CN f(114–121)) | ACE inhibitory and Opiate like activity | ND                                              | (Papadimitriou et al. 2007) |
| Kefir and Koumiss                            | Goat milk Kefir        | ND                              | ACHE inhibitory                                 | ND                                              | (Shi et al. 2018) |
| Goat milk Kefir                              | ND                     | Antioxidant activity            | 75%                                             | (Satir and Guzel-Seysdim 2015) |
| Goat milk Kefir                              | AASGSIAQAQLP (β-ly f(43–58)) | Anti-bacterial activity          | ND                                              | (Izquierdo-González et al. 2019) |
| Goat milk Kefir                              | INNQLPYPY (α-CN f(842–511)) | Dipeptidyl peptidase IV inhibitor | ND                                              | ND                                              | (Guha et al. 2021) |
| Goat milk Kefir                              | TAOVTSTEV (α-CN f(154–162)) | Anti-thrombotic                 | ND                                              | ND                                              | (Guha et al. 2021) |

ND = Not defined
showed a similar peptide profile. ACE inhibitory activity increased during ripening to a certain level and decreased thereafter due to breakdown of responsible peptides to lower molecular weight fragments (Kocak et al. 2020).

A water-soluble peptide extract of Pecorino Romano cheese, made from sheep milk, was found to be potentially active against certain pathogenic bacteria such as Bacillus megaterium, E. coli, Yersinia enterocolitica, Lactobacillus innocua, Staphylococcus aureus, and Salmonella spp with minimum inhibitory doses ranging from 20 to 75 μg/mL (Rizzello et al. 2005).

Water soluble extracts of different market samples of feta, Roquefort, Pecorino Sardo-Cerrillano, and Pecorino cheese of sheep’s milk possessed prominent antioxidant and ACE inhibitory activities. However, water soluble extracts of Roquefort-type displayed the best anti-hypertensive and antioxidative properties due to its complex peptide profile. Total nine peptides from β-casein fraction, five peptides from αs2-casein and three from αs1-casein were identified having antioxidant and ACE inhibitory peptides sequence homology identified in other cheeses. All the bioactive peptides had at least one proline amino acid residue which had been reported to contribute to ACE inhibitory and antioxidant activity (Meira et al. 2012). Sheep milk-based probiotic, Scamorza cheese, showed the potential of yielding bioactive peptides. Probiotic cultures (Bifidobacterium longum BL-46 and Bifidobacterium lactis BB-12) liberated higher amount of low molecular peptides during secondary proteolysis as compared to control cheese. The β-casein f(210–220), αs1-casein f(1–23), κ-casein f(78–90) and αs1-casein f(1–6) protein fragments were observed in Scamorza cheese (Albenzio et al. 2015). Atanasova et al. (2020) identified 31 and 22 bioactive peptides in sheep and goat milk-based white brined cheese of Bulgarian origin, respectively. Peptides were majorly obtained from hydrolysis of αs1-casein, αs2-casein and β-casein. The identified peptides were having ACE inhibitory, αs1-casokinin, caseinophosphopeptide and immune peptide activity (Table 4).

Fermented milk (yoghurt)

Bioactivities of fermented milk increase during initial storage period due to the active degradation of the starter, followed by a decrease after a certain interval due to modification and degradation of the bioactive fractions (Sultan et al. 2017). Bioactive peptides derived from Lactobacillus acidophilus and Streptococcus thermophilus fermented camel milk showed ACE inhibitory and antimicrobial activities against Bacillus cereus, Salmonella Typhimurium, and Staphylococcus aureus. Bioactivities were time and strain-dependent wherein microbial inhibition activity was observed after 12 h of incubation till 15 days (Alhaj et al. 2018). Camel milk fermented by Leuconostoc lactis, isolated from traditional fermented camel milk (Chal), had antioxidant activity as revealed by significantly higher ABTS and DPPH activity (Soleymanzadeh et al. 2016). Antioxidant potential of camel milk increased after fermentation. Reducing power assay and percentage DPPH inhibition of yoghurt prepared from camel milk increased significantly (p < 0.01) on heating the camel milk at 80 °C for 30 to 120 min. On heating, protein unfolding and exposure of thiol groups acts as hydrogen donor while on severe heating, oxidants get consumed during Maillard reaction, producing melanoindin with strong antioxidant activity. However, percentage inhibition decreased during cold storage of yoghurt. The bioactive peptides in yoghurt possessed antimicrobial potential against B. cereus, E. coli, and S. aureus (Elhamid & Mervet, 2017). Camel milk fermented with Lactobacillus plantarum had 32 peptides belonging to lacticin (6), αs2-casein (7), β-casein (9), αs1-casein (10) proteins and showed antimicrobial activity against Gram-positive and Gram-negative bacteria including S. aureus, E. coli, Shigella dysenteriae, and Staphylococcus faecalis (Algooboy and Muhlaldin 2018).

Casein derived bioactive peptides from goat milk yoghurt reduced the renal and aorta malondialdehyde in deoxyriboosistereone hypertensive rats (Padaga and Sujuti 2015). Goat (Beetal breed) and sheep (Kajli breed) yoghurt prepared using Streptococcus thermophilus and Lactobacillus bulgaricus showed anti-hypertensive and antioxidative potential. Peptide concentrations in goat and sheep yoghurt were 6.50 mg/mL and 5.13 mg/mL, respectively, which increased during storage because of enzymatic proteolysis (Sultan et al. 2017). Three different 16 amino acids containing bioactive peptides in goat milk yoghurt from β-casein (LYQEPVLGVPVRGPFPPI, YQEPVLGVPVRGPFPIL, and VQSMHQPQQPLSPT) had antioxidant potential and protected rats from hypercholesterolemia (Mahdi et al. 2018). Goat milk fermented with five different Lactobacillus cultures showed different concentrations of antihypertensive and X-propyl-dipeptidyl aminopeptidase activity due to modification in their proteolyis level (Parmar et al. 2020). Goat milk yoghurt prevented 2,3,7,8-tetrachlro-dibenzo-p-diozin induced lung damage in male rats due to antioxidant activity of yoghurt casein (Haskito et al. 2020). Sheep milk based Greek yoghurt prepared with standard yoghurt culture and Lactobacillus paracasei subsp. paracasei DC412 possessed higher content of bioactive peptides in comparison to standard yoghurt culture-based product. Most of the peptides were derivative of casein and the fragment 114–121(YPVEPFT) had ACE inhibitory and opioid like activity. However, the peptide content and anti-hypertensive properties of water-soluble extracts of Greek yoghurt increased during
storage (Papadimitriou et al. 2007). Sheep milk yoghurt led to faster colonic transit in rats due to absence of β-casomorphin precursor as it promotes the feeling of satiety and calms down any colonic over-activity. Several identified bioactive peptides in sheep yoghurt included αs1-casein f25–32 (VVAPFPEVF) with ACE inhibitory properties, αs1-casein f180–193 (SDIPPGHNSGK) with anti-microbial activity, β-casein 1f66–175 (SQPKVLPVPQ) and β-casein 183–190 (RDPIQAF) with antioxidant potential, β-casein 192–209 (LYQEPVLPGPV RGPFPILV) with immunomodulation properties, and β-casein 193–207 (YQEPVLPGRPFPFL) as an antimicrobial (Dalziel et al. 2018). Nguyen et al. (2020) reported that lower peptide release in sheep milk yoghurt during the early phase of gastric digestion was due to the dense network and higher gel firmness as compared to goat yoghurt. Dense gel network and cross-linked structures hinder the accessibility of enzyme to cleave protein, thereby slowing the peptide release. Both sheep and goat yoghurts contained a higher number of identified peptides as compared to their corresponding milk. The β-casein f96–104 (PVVPPFPNFLQ) showed antihypertensive activity in goat and sheep milk yoghurt.

Donkey milk fermented with different Lactobacillus isolates exhibited antioxidative, antihypertensive, and antimicrobial properties. The coupled action of fermentation and in vitro simulated gastrointestinal digestion further enhanced the rich pool of bioactive peptides available in donkey milk. The highest numbers of peptides were derived from β-casein and β-lactoglobulin, as their structures were more accessible to hydrolyzing enzymes (Aspri et al. 2018). Mare milk yoghurt possessed lower ACE inhibitory activity as compared to cow and soy milk due to absence of ACE-inhibitory tripeptides IPP and VPP in mare milk (Wang et al. 2015).

**Kefir and koumiss**

Kefir is a naturally carbonated fermented milk product produced using Kefir grains. Kefir grains consist of complex microflora which is responsible for the antihypertensive, antibacterial, and anti-inflammatory properties of Kefir (Biadala et al. 2020). Kefir grains from different regions of China revealed 3% inoculum of K1 grains at 25 °C for 22 h for the best production of goat milk-based kefir. K1 kefir grains also outperformed kefir grains from other locations in terms of ACE inhibitory and antioxidant activity (Shi et al. 2018). Goat milk of two different breeds, Hair and Saanen, showed significant increase in their antioxidant activity after being fermented with 2% natural Kefir grains (Satir and Guzel-Seydim 2015). Goat milk fermented with different strains of kefir grain namely Lactobacillus kefiranofaciens subsp. Kefirgranum DSM 10,550, Lactobacillus kefiri PCM 2501, Lactobacillus parakefiri DSM 10551, Lactobacillus brevis PCM 488, Lactobacillus delbrueckii subsp. lactis PCM 2611 showed antimicrobial activity against E. coli, Salmonella, Micrococcus luteus and Proteus mirabilis (Biadala et al. 2020). Different bioactivities of kefir were reported in literature, however, identification and characterization of such peptides is limited. Izquierdo-González et al. (2019) profiled the bioactive peptides in goat milk kefir after 12, 24 and 36 h of fermentation using peptidomics approach. In total, 11 bioactive peptides (Table 4) were identified after different fermentation time; however, maximum concentration was obtained after 24 h which decreased thereafter. The number of peptides was almost similar to control after 12 h fermentation as kefir was not mature and the proteolysis was low.

**Future trends**

The ability to generate bioactive peptides by food commodities is considered an important parameter owing to their functional and nutritional properties. Proteins from cow milk have been studied extensively as sources of bioactive peptides. On the other hand, minor milk proteins and their related products have always been considered as the “dark” areas of research because of their low economic significance. However, in recent years this trend has been changing, as there is an increase in demand in finding alternative milk sources and milk products, particularly for their bioactive peptides. Various bioactive peptides, derived from different milk protein sources other than cow milk, have already shown diverse biological activities such as ACE-inhibitory, metal-binding, antioxidant, antimicrobial activities among many more, which have revealed unique peptides. However, there still exists a huge gap in knowledge in terms of stability, bioavailability, and efficiency of these peptides, particularly in in vivo experiments and clinical trials, which paves a huge path for understanding the role of these peptides in human health. A better understanding of these minor milk protein-derived peptides would also aid the commercialization of the peptides for dietary uses. This could be done by the following approaches:

- The use of recombinant enzymes and specific microbial fermentations, such as use of special coagulating enzymes during cheese fermentations, could be a useful technique to give rise to novel peptides from different milk and their associated products.
- Understanding the structure-function relationship of the peptides for a better insight into the biochemical functions and their dietary implications using powerful tools, such as cell culture, -omics, imaging, and gut microbiome research.
• Examining the toxicity, allergenicity, and stability of the peptides during gastrointestinal digestion of the formulations after incorporating the bioactive peptides into them.

Thus, minor milk protein-derived bioactive peptides hold an enormous potential in the development of nutraceuticals and functional foods which could be used as a health ingredient. Also, characterization of bioactive peptides derived from minor milk species would help in their popularity and recognition across the globe.

Conclusion
The research on milk and milk products from minor dairy species have been less promoted due to lesser animal population with corresponding limited significance in the economy. The availability of minor dairy animal’s milk and milk products is also limited to local and regional areas. However, the growing interest of consumers towards authentic traditional foods and substitute of bovine milk with multifunctional properties, has lightened them globally. Bioactive peptides liberated from bovine milk proteins have been reported to possess various activities, such as, antihypertensive, antioxidative, antimicrobial, mineral binding, and immunomodulatory, etc. which represent its health and nutritional importance. However, more sophisticated and long-term animal and human studies are needed to validate these health benefits. Although rational information on bioactive peptides from goat and sheep milk proteins is available now, limited research has been done on bioactive peptides from other minor dairy animal’s milk and milk products. Identification, characterization and application of bioactive peptides requires more attention of scientific community which would be helpful in commercial application of milk protein derived bioactive peptides from milk and milk products of minor dairy animals to improve human health.

Acknowledgements
The graphical abstract has been created in Biorender.com and exported under a paid subscription.

Authors’ contributions
SG, HS and PSR conceived and designed the paper; SG, HS, and GKD collected and analyzed literatures and wrote the paper; PSR, HS, SG edited the table and figure, PSR reviewed and edited the manuscript. The authors read and approved the final manuscript.

Funding
The authors declare that no funding was provided for the present work.

Availability of data and materials
Data and materials used include all the original reviewed articles which are available.

Competing interests
The authors declare no competing interests.

Author details
1Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE 68588-6205, USA. 2Food Technology Laboratory, Dairy Technology Division, National Dairy Research Institute (ICAR-NDBR), Kamal, Haryana 132001, India. 3Dairy Chemistry and Bacteriology Section, Southern Regional Station-National Dairy Research Institute, Bengaluru 560030, India.

Received: 30 September 2020 Accepted: 29 November 2020
Published online: 11 January 2021

References
Abd Elhamid, A. M., & Mervet, M. E. (2017). Effect of heat treatment and fermentation on bioactive behavior in yoghurt made from camel Milk. American Journal of Food Science and Technology, 5(3), 109–116.
Albujat, L. (2019). Antimicrobial and anti-inflammatory activity of camel milk derived immune proteins and peptides against Propionibacterium acnes. International Journal of Biology, Pharmacy and Allied Sciences. https://doi.org/10.31032/jjbspac/2019/81.4623.
Ahmed, A. S., El-Bassioni, T., Elmalt, L. M., & Ibrahim, H. R. (2015). Identification of potent antioxidant bioactive peptides from goat milk proteins. Food Research International, 74, 80–88 https://doi.org/10.1016/j.foodres.2015.04.032.
Al Haj, O. A., & Al Kanhal, H. A. (2010). Compositional, technological and nutritional aspects of dromedary camel milk. International Dairy Journal, 20(12), 811–821 Elsevier. https://doi.org/10.1016/j.idairyj.2010.04.003.
Alberro, M., Santillo, A., Marino, R., Della Malva, A., Caporese, M., & Sevi, A. (2015). Identification of peptides in functional Scamorza ovine milk cheese. Journal of Dairy Science, 98(2), 8428–8432 https://doi.org/10.3168/jds.2015-8984.
Algrooby, H. L., & Muhaidin, B. J. (2018). Identification of low molecular weight antimicrobial peptides from Iraqi camel milk fermented with lactobacillus plantarum. PharmaNutrition, 6(2), 69–73 https://doi.org/10.1016/j.phanu.2018.02.002.
Alhaj, O. A. (2017). Identificación de los péptidos inhibidores de ACE potenciales en leche fermentada de dromedario. CyTA Journal of Food, 15(2), 191–195 https://doi.org/10.1080/19476337.2016.123633.
Alhaj, O. A., Metwalli, A. A., Ismail, E. A., Ali, H. S., Al-Khalifa, A. S., & Kanekanian, A. D. (2018). Angiotensin converting enzyme-inhibitory activity and antimicrobial effect of fermented camel milk (Camelus dromedarius). International Journal of Dairy Technology, 71(1), 27–35 https://doi.org/10.1111/1471-6307.12383.
Alichanidis, E., Moatsou, G., & Polychroniadou, A. (2016). Composition and properties of non-cow milk and products. In Non-bovine milk and milk products. Elsevier Inc https://doi.org/10.1016/B978-0-12-803361-0.00005-3.
Ayash, M. Z., Shoukat, S., Hongfei, Z., & Bolin, Z. (2018). Proteomic analysis of ACE inhibitory peptides extracted from fermented goat milk. In Peptidomic analysis of ACE inhibitory peptides extracted from fermented goat milk. (p. 336107) https://doi.org/10.1101/336107.
Aspit, M., Leni, G., Galaverna, G., & Papademar, P. (2018). Bioactive properties of fermented donkey milk, before and after in vitro simulated gastrointestinal digestion. Food Chemistry, 268, 476–484 https://doi.org/10.1016/j.foodchem.2018.06.119.
Atanassova, J., Dalgalarrondo, M., Iliev, I., Moncheva, P., Todorov, S. D., & Ivanova, I. V. (2020). Formation of free amino acids and bioactive peptides during the ripening of Bulgarian white brined cheeses. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12262-020-00966-0.
Augustin, M. A., & Udabage, P. (2007). Influence of processing on functionality of milk and dairy proteins. Advances in Food and Nutrition Research, 53, 1–38 https://doi.org/10.1016/S0065-2156(07)53001-9.
Bao, C., Chen, H., Chen, L., Cao, J., & Meng, J. (2016). Comparison of ACE inhibitory activity in skimmed goat and cow milk hydrolyzed by Alcalase, flavourzyme, neutral protease and proteinase K. Acta Universitatis Cibiniensis. Series E: Food Technology, 20(1), 77–84 https://doi.org/10.1515/autcf-2016-0006.
BEG, O. U., von BAHR-LINDSTRÖM, H., ZAIDI, Z. H., & JÖRNVALL, H. (1985). The primary structure of α-lactalbumin from camel milk. European Journal of Biochemistry, 147(2), 233–239. https://doi.org/10.1111/j.1432-1033.1985.tb08741.x.
Biadała, A., Szablewski, T., Lasik-Kurdyl, M., & Cegielska-Radziejewska, R. (2020). Antimicrobial activity of goat’s milk fermented by single strain of kefir grain microflora. European Food Research and Technology, 246(6), 1231–1239 https://doi.org/10.1007/s00217-020-03483-2.
